anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The sars-Cov-2 pandemic has determined psychological stress, particularly in the young population of medical students. We studied the impact of the pandemic on menstrual cycle alteration in relation to psychological stress, presence of depression, sleep disturbances and post-traumatic stress, on a population of medical students.
METHODS: 293 female students at the Faculty of Medicine and Psychology of the Sapienza University of Rome (23.08 years old ± 3.8) were enrolled. In March 2021, one year after quarantine, a personal data sheet on menstrual cycle, examining the quality of the menstrual cycle during the pandemic, compared to the previous period. Concomitantly, the Beck Depression Inventory and the Impact of Event Scale have been administered. A Pearson chi-square test was assessed to evaluate the difference between the characteristics of the menstrual cycle and the scores obtained with the questionnaires.
RESULTS: A statistically significant association between menstrual alterations and stress during pandemic had been found. The onset of depressive symptoms and sleep disturbances was observed in 57.1% and in 58.1% of young women with cycle's alterations, respectively. Amenorrhea was three times more common in female students with depressive symptoms, premenstrual syndrome had a significant correlation with both depression and sleep disturbances. The pandemic has been related to menstrual alterations, with depressive symptoms and sleep disorders. Amenorrhea is connected to depression, as observed on the functional hypothalamic amenorrhea.
CONCLUSIONS: The pandemic affected the menstrual cycle as well as the depressive symptoms and sleep. Practical implications of the study lead to the development of strategies for psychological intervention during the pandemic experience, in order to help medical trainees, with specific attention to women's needs. Future studies should analyze the impact of other types of social stress events, on sleep, depression and the menstrual cycle beside the pandemic.
Disclosed is a vaccine which is safe and effective on malaria infection. Also disclosed is a vector for use in the production of the vaccine. Further disclosed is a bivalent vaccine which has an excellent protective effect on a measles virus and malaria infection and is free of complications upon inoculation. Specifically disclosed is a recombinant measles virus produced by inserting a gene encoding a protein involved in the protection against onset of malaria infection into a measles virus genome. The protein involved in the protection against onset of malaria infection is preferably selected from pfEMP-1, MAEBL, AMA-1, MSP-1, LSA-1, Pfs230 and others. Also specifically disclosed are a bivalent vaccine against measles and malaria infection, which comprises the recombinant measles virus. Further specifically disclosed is an anti-serum produced from a body fluid collected from an animal infected by the recombinant measles virus. Still further specifically disclosed is a method for producing a vaccine against malaria infection, which is characterized by using a measles virus as a vaccine vector.
Patients suffering from a locally invasive tumour process in the Periampullary area usually seek medical attention because of jaundice. Not only do patients suffering from jaundice show significant symptoms of exhaustion and purities, but they are also at higher risk for developing post-operative complications. Experimentally, the liver exhibits a reduced capacity for tolerating ischemia in the presence of jaundice. Several different etiologic factors suggest cause complication such as presence of toxic substances as bilirubin and bile salts, impaired nutritional status, effects of endotoxins, bacterial translocation, modulation of the inflammatory cascade with cytokine release, reduction of cellular immunity and nutritional. These complications primarily consist of septic complications (cholangitis, abscesses, and leakage), haemorrhage, impaired wound healing and renal disorders. Summarily, these issues have motivated pre-operative bile flow drainage by way of stent. Traditionally, pre-operative bile flow drainage has been achieved by insertion of a EP because these are considered easy to remove and cause less tissue reaction in the bile ducts. However, multiple studies have found the disadvantage with the EP is that it provides poorer bile drainage than the SEMS.

In palliative situations, metal stents have been associated with fewer side-effects in the form of fever relapse of jaundice, etc. These effects are likely due to better bile flow through the stent. It remains unclear if metal stents can provide similar advantages in the curative situation.
<P>PROBLEM TO BE SOLVED: To newly develop a cosmetic markedly enhanced in cosmetic benefits inherent of a placenta extract (especially skin whitening effect, moisturizing effect, and anti-oxidative effect) and having high safety.  <P>SOLUTION: The problem is solved by a cosmetic prepared by enclosing a placenta extract and a Coix lacryma-jobi seed powder in liposomes. An example of the cosmetic is as follows. A lipid film component comprising a phospholipid and/or a glycolipid is dissolved in a solvent, and a water phase containing a water-soluble placenta extract and a Coix lacryma-jobi seed extract is added to the solution under agitation. The resultant mixture is subsequently heated and agitated to disperse the lipid component to form fine liposomes. The liposomes, which have an average particle diameter of 100 nm or smaller, are separated and recovered to obtain the placenta extract/Coix lacryma-jobi seed powder-enclosed liposomes. These are used as a raw cosmetic material to produce various cosmetics.  <P>COPYRIGHT: (C)2010,JPO&INPIT
BACKGROUND: Sigmoid sinus wall dehiscence can lead to pulsatile tinnitus with a significant decrease in quality of life, occasionally leading to psychiatric disorders. Several surgical and endovascular procedures have been described for resolving dehiscence. Within endovascular procedures, the sagittal sinus approach could be a technical alternative for tracking and accurate stent positioning within the sigmoid sinus when the jugular bulb anatomy is unfavorable.
CASE PRESENTATION: A retrospective case series of three patients with pulsatile tinnitus due to sigmoid sinus wall dehiscence without intracranial hypertension was reviewed from January 2018 to January 2022. From the participants enrolled, the median age was 50.3 years (range 43-63), with 67% self-identifying as female and 33% as male. They self-identified as Hispanic. Sigmoid sinus dehiscence was diagnosed using angiotomography, and contralateral transverse sinus stenosis was observed in all patients. Patients underwent surgery via a navigated endovascular sagittal sinus approach for sigmoid sinus stenting. No neurological complications were associated with the procedure. Pulsatile tinnitus improved after the procedure in all patients.
CONCLUSIONS: Superior sagittal sinus resection for sigmoid sinus wall stenting is a safe and effective technique. Pulsatile tinnitus due to sigmoid sinus wall dehiscence could be treated using the endovascular resurfacing stenting technique. However, further research is needed to evaluate the potential benefit of contralateral stenting for removing sinus dehiscence when venous stenosis is detected. However, resurfacing sigmoid sinus wall dehiscence results in symptomatic improvement.
Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
Eye defects occur when the eye cannot focus images from the outside world. This results in blurred vision, which sometimes is so severe that it causes visual impairment. Among the many vision defects, presbyopia is an inevitable, irreversible, universal age-related condition where the crystalline lens in the eye loses its accomodation orthe ability to change the optical power. This defect occurs as a natural result of aging and will ultimately affect any person reaching advanced enough age. It was estimated in 2005 that over 1 billion people worldwide suffered from presbyopia, with approximately 400 million suffering from near vision loss due to the lack of correction technologies.

The most inexpensive and commonly used tools to correct vision errors are fixed power eyeglasses, which haven't seen any improvement since the mid-1800s. Conventional eyeglasses are an ancient piece of technology which originated in Europe's middle ages. A major drawback of such eyeglasses is that they can only correct the lack of accomodation at a particular object distance, since they use fixed power lenses. As a result, conventional eyeglasses can produce sharp images for objects located either far away or near the observer but not both. Bifocal, multifocal and progressive lenses can partially alleviate vision defects, but at the expense of reduced and fragmented field of view. As an example, multifocal lenses have different lens powers in different regions of the lens. With such lenses, it is not possible to see objects clearly over the entire visual field. Further, the effectiveness of conventional eyeglasses is not monitored outside the optometrist's office.

The proposed smart eyeglasses system uses a combination of large-aperture fluidic lenses, ultra-light actuators, object distance sensors and embedded control, communications and computing electronics to continuously produce sharp and focused images at any object range. They can also collect the behaviour and characteristics of the observer's eyes to gauge the effectiveness of the technology and adapt to observer's visual degradation over age.
Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
The invention belongs to a traditional Chinese medicine type alcohol intoxication alleviating tea beverage, mainly relates to the field of traditional Chinese medicines and beverages, and belongs to a traditional Chinese medicine and tea beverage. A purpose of the present invention is to provide a tea beverage having a good alcohol intoxication symptom alleviating effect. In order to achieve the purpose, the main raw materials of the tea beverage comprise 17-21% of radix puerariae, 13-19% of ziziphus montana w. w. smith, 24-31% of dioscorea zingiberensis, 15-24% of sea pomegranate, 11-24% of planchonella obovata (r. br.) pierre, 15-25% of swertia yunnanensis burk, 9-13% of organge peel, 7-13% of fructus lycii barbari, and 4-7% of licorice root. The traditional Chinese medicine type alcohol intoxication alleviating tea beverage of the present invention has the advantage of good alcohol intoxication symptom alleviating.
Ten participants to receive the IMP - EMI-137 1 to 3 hours before laparoscopic colonic resection surgery. Dose range 0.02mg/kg to 0.13mg/kg will be administered.
INTRODUCTION: Sinonasal organizing hematoma (OH) is a rare, nonneoplastic lesion that often presents with epistaxis, a reddish mass, and destruction of the involved sinonasal structures. Due to its rarity, the demographics, diagnostic modalities, treatment strategies, and outcomes have not yet been studied in a large, long-term study.
MATERIALS AND METHODS: Retrospect cohort of 112 sinonasal OH patients treated between 1997 and 2020 in a tertiary, university hospital were evaluated. Demographics, systemic comorbidities, sinonasal surgery history, serum laboratory tests, radiological findings, and treatment results were collected. The present study aimed to assess the accuracy of preoperative computed tomography (CT), Gadolinum-enhanced magnetic resonance (MR), and punch biopsies in detecting sinonasal OH as the most likely diagnosis. In addition, incidental differences by age and year of diagnosis were calculated using the Poisson log-linear regression model.
RESULTS: The median age was 44, and 58% were male. Fewer than 20% of these cases had a chronic systemic comorbidity, bleeding tendency, or sinonasal surgery history. MR had the highest accuracy of (87%) to detect sinonasal OH as the most likely diagnosis, compared with contrast-enhanced-CT (53%), punch biopsy (49%), and non-enhanced-CT (16%) (all <0.05). Sinonasal OH incidence did not vary by age, but the yearly rate significantly increased by 1.05 times over 23 years (p < 0.05). Notably, 84% of 112 patients received surgical removal through the assistance of an endoscope, and none had substantial bleeding without preoperative embolization.
CONCLUSION: Sinonasal OH was observed regardless of age, sex, systemic comorbidities, bleeding tendency, prior sinonasal surgery, or trauma. Preoperative MR gives the highest accuracy for detecting this disease. Sinonasal OH may be safely managed with endoscopic-assisted surgery removal without embolization.
LEVEL OF EVIDENCE: 4 Laryngoscope, 134:1581-1590, 2024.
PROBLEM TO BE SOLVED: To obtain a nano-emulsion having high storage stability, capable of holding a large amount of oil, keeping high transparency and exhibiting good cosmetic characteristics by including a specific surfactant and a specific oil phase at a specific ratio and dispersing the oil phase in a water phase in the form of oily droplet smaller than a specific size. SOLUTION: The objective nano-emulsion contains (A) a surfactant selected from mixed esters of a fatty acid or fatty alcohol, a carboxylic acid and glycerol and (B) an oil phase containing an oil having a molecular weight of >400 (e.g. isocetyl stearate) at a weight ratio (B:A) of 2-10. The oil phase is dispersed in a water phase in the form of oily droplets having a number average diameter of smaller than 100 nm. The component A is preferably a mixed ester of succinic acid, isostearyl alcohol and glycerol, etc. The nano-emulsion is cosmetically used for the care, treatment and/or make-up of skin, head and/or scalp.
Trastuzumab, at the investigator's discretion, either 2 milligrams per kilogram (mg/kg) intravenous (i.v.) every 7 days or 6 mg/kg i.v. every 3 weeks. Chemotherapy, schedule and dose at the investigator's discretion.
Patients diagnosed with HR+/HER2- locally advanced or metastatic breast cancer indicated by their treating physicians for first line endocrine-based palbociclib combination therapy and who meet eligibility criteria will be invited to participate in this study. The key objectives of this study are to describe clinical, scientific and patient reported outcomes for patients with HR+/HER2- locally advanced or metastatic breast cancer initiating treatment with first line endocrine-based palbociclib combination therapy in the real-world setting in Germany and Austria. Patient characteristics, real-world treatment patterns, treatment sequences and reasons for the physician's treatment decisions will be collected. Additional real-world research questions are to explore patient-focused parameters such as longitudinal follow-up data on patient-reported outcomes beyond disease progression and by treatment sequence or to analyze the time from the start of first line treatment to the first administered palliative chemotherapy. Clinical outcome by treatment sequences will be described. Routinely assessed biomarkers and diagnostic procedures applied for treatment sequence decisions will be collected.
The study uses semi-automated detection of anatomical metrics (morphometric parameters) and DCC with Spinal Cord Toolbox (SCT). This method have been proven more reliable than expert's manual rating, the introduction of the automated method will be utilized in the future multi-centre and longitudinal studies. Routine anatomical morphometric parameters such as compressive ratio (CR) and cross-sectional area (CSA) will be acquired along with microstructural and metabolic metrics obtained with validated dMRI and MRS methods, remote cervical cord atrophy from voxel-based MRI volumetry, T2\* white matter/gray matter (WM/GM) signal-intensity ratio, and also metrics obtained with novel Intravoxel Incoherent Motion (IVIM) method will predict progression of NMDCC into symptomatic DCM. "Natural course" (i.e., speed of progression) of the severity of DCC assessed with anatomical and advanced MRI/MRS metrics is not known but may play a role in the progression from NMDCC to symptomatic DCM. Aims of this project are: To determine independent predictors of unfavourable outcome - progression into symptomatic degenerative cervical myelopathy (DCM) - among quantitative MRI parameters and compare them with already defined clinical and electrophysiological predictors. To evaluate the "natural course" of MRI descriptors of compression and its severity, and the correlation between progression and development of symptomatic DCM. To implement automated detection of cervical cord compression using Spinal Cord Toolbox based on automatically computed morphometric parameters.
Over one million individuals in the U.S. have ostomies. The American Cancer Society estimates 39,610 rectal cancer cases and 74,000 bladder cancer cases will be diagnosed in 2015. Of these, at least 30,000 will receive ostomies, and an additional unknown number due to gynecologic, other gastrointestinal tumors. The HRQOL impact is tremendous and greater than with many other cancer treatments. An ostomy is often a prolonged or lifelong disabling problem for cancer survivors. The adaptation period is quite variable. 18% of participants took at least one year, or never felt comfortable, in their ostomy care. Importantly, many patients cannot attend selfmanagement programs or patient groups for a myriad of reasons, including distance to travel, monetary outlays, comorbidities making travel difficult, or lack of access to transportation. In addition, a national shortage of OCNs means patients with an ostomy, whether newly placed or a long-term issue, receive little help.

It is imperative to study interventions for these cancer survivors aimed to limit family financial burdens, decrease medical care use, and improve well-being. This study has the potential to improve health care outcomes for cancer survivors with ostomies by enhancing their knowledge of and self-efficacy with ostomy care. This will be accomplished by improving the ability to communicate an established educational curriculum developed based on patient needs and desires and refined via a pilot study.
<P>PROBLEM TO BE SOLVED: To provide a food or drink and a treating or preventing agent safely usable for the prevention or treatment of cerebrovascular dementia over a long period.  <P>SOLUTION: The food or drink for the prevention or treatment of cerebrovascular dementia contains carnosine as an active component and suppresses the death of neurocyte caused by zinc excessively released after ischemia. The carnosine to be used in the invention may be a synthetic product or a natural material, however, it is preferably a natural material from the viewpoint of safety. The preferable natural carnosine is, from the viewpoint of practicality, a material extracted, separated and purified from an inexpensive raw material such as broth discharged in the production of dried bonito or dried sardine, broth discharged in the manufacture of canned tuna, mackerel, etc., or waste chicken meat. There is no particular problem on the dosage form, form of food or drink and the addition amount of a third component unless these are allowable from pharmacological or food hygienic viewpoint, however, it is preferable from the viewpoint of continuous administration to use the broth, etc., as a raw material as it is without purification and mixing with other nutrition components and flavoring components to serve the mixture as a functional food or drink.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Participants will receive bermekimab dose 1 SC at Week 0 and every week thereafter through Week 11. From Week 12, participants will receive bermekimab dose 1 SC every other week thereafter through Week 30. During weeks in which bermekimab is not administered, participants will receive placebo SC through Week 31.
INTRODUCTION: Postoperative nausea, vomiting, and cough are the most common adverse effects of general anesthesia resulting in high discomfort to the patient resulting in uneasiness during the recovery period. This study aimed to compare the influence of intraoperative use of sevoflurane and isoflurane on postoperative nausea, vomiting, and cough.
MATERIALS AND METHODS: After approval from the institutional ethical committee, this quantitative observational institutional study was conducted on all patients aged between 18 and 65 years undergoing surgery under general anesthesia at KMC Hospital, Mangalore. Patients were allocated into the sevoflurane group or isoflurane group.
RESULTS: All demographic parameters such as age, sex, American Society of Anesthesiologists physical status, and duration were comparable (P > 0.05). The sevoflurane group had higher number of patients (11 [14.86%]) with postoperative nausea at 0 h as compared isoflurane group (7 [9.45%]). Two patients in the isoflurane group reported postoperative vomiting at 0 h, whereas no patient in the sevoflurane group reported vomiting. For cough, a statistically significant correlation was seen between the two groups (P = 0.000) with majority of patients in the isoflurane group, i.e., 50 (67.6%) patients reporting cough at 0 h while only 15 (20.3%) reported cough in the sevoflurane group.
CONCLUSION: Sevoflurane was found to be better than isoflurane in terms of postoperative nausea vomiting and cough immediately after emergence in our study. Isoflurane cause the emergence of cough whereas no significant difference in nausea and vomiting was observed in both groups.
The invention provides an emulsifier which exhibits high storage stability in a wide range of emulsification combinations and has excellent emulsification performance, and an emulsified composition containing the emulsifier. An emulsifier comprising a diblock copolymer of the formula [ I]A silicone graft copolymer block represented by the formula [ II]The polar copolymer block represented by the formula [ III ] constitutes a main chain, and the terminal structure at one end of the main chain is represented by]The structure of the other end is represented by the formula [ IV]The structure shown. (in the formula, R  1  Represented by a hydrogen atom or a methyl group, A is represented by an organopolysiloxane-containing group, n  1  Expressed as 1. Ltoreq. N  1  Not more than 50, B represents a monovalent hydrocarbon group having 1 to 20 carbon atoms and having a polar group, an amino group or a hydroxyl group, n  2  Expressed as 1. Ltoreq. N  2  ≤50，R  6  Is represented by an alkyl group having 1 to 4 carbon atoms, R  7  Independently represent a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and X represents a group represented by the formula [ I]A in (A) or formula [ II]The group represented by B in (1).